Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 723 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected... February 2, 2026 Why Have Thyroid Cancer Diagnoses Spiked for US Women? September 28, 2021 How do we die of cancer? What we know (and what... May 8, 2022 FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease July 19, 2021 Load more HOT NEWS Monoclonal Antibodies May Lower Recurrence Risk for Some Early Stage Breast... TMB Consortium Develops a TMB Calibration Tool Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’ When Breast Cancer Patient Comes Into His Shop, Barber Shaves His...
